NASDAQ Approves NeoTherapeutics Listing on Small-Cap Market
IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) announced today that the Company has met all requirements for listing on the NASDAQ Small-Cap Market and that NASDAQ has approved the Company's Small-Cap Market application. The Company will begin trading on the exchange on October 16, 2002 and will continue to trade as before under the ticker symbol NEOT.
NeoTherapeutics seeks to create value for shareholders through the development of in-licensed drugs for the treatment and supportive care of cancer patients. The Company's lead drug, Satraplatin, is a phase 3 oral anti- cancer drug. Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. Neoquin is being studied in the treatment of superficial bladder cancer, and may have applications as a radiation sensitizer. The Company also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain, which it is actively seeking to out-license or co- develop. For additional information visit the Company's web site at www.neot.com.
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
(949) 788-6700, ext. 247